ABSTRACT
It is not easy to summarize the experimental and clinical data regarding the influence of the widely used IOP-lowering drugs on ocular perfusion. The results of the functional investigations are not infrequently conflicting, the human intraocular concentration of most of these drugs is unknown and the conclusions derived from adequately designed, long-term studies are missing. However, the ophthalmologist requires guidelines on this field since the drug-induced changes of the ocular blood supply are of clinical importance. Table 12.1 provides a simplified summary of the most relevant information in this area. Further long-term and adequately controlled studies are necessary to clarify the role of the presently available and future antiglaucoma drugs in the treatment of glaucomatous vascular dysregulation.
